<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30117264</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1476-5829</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Veterinary and comparative oncology</Title>                <ISOAbbreviation>Vet Comp Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Expression of the Hippo signalling effectors YAP and TAZ in canine mammary gland hyperplasia and malignant transformation of mammary tumours.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/vco.12432</ELocationID>            <Abstract>                <AbstractText>Canine mammary tumours (CMTs) are common neoplasms in dogs that feature many of the clinical, genetic and molecular characteristics of human breast cancer. Despite their high metastatic potential, few adjuvant chemotherapeutic treatment options exist for malignant CMTs, and the development of novel, targeted pharmacological approaches will require a better understanding of their pathogenesis. As recent evidence suggests that dysregulated Hippo signalling is involved in the development and progression of breast cancer, we sought to determine if this pathway could also play a role in CMT. The expression of the Hippo signalling effectors YAP and TAZ was analysed by immunoblotting and immunohistochemistry in samples including normal mammary gland, lobular hyperplasia, benign tumours and malignant tumours of all grades. We found a significant increase in TAZ (but not YAP) expression occurred in lobular hyperplasia relative to normal mammary gland, suggesting a role for TAZ in non-neoplastic epithelial proliferation. Nuclear expression of both TAZ and YAP were significantly higher in malignant tumours than in benign ones, suggesting that Hippo dysregulation could play a role in CMT malignant transformation. No differences in YAP or TAZ expression were detected between grades of malignant tumours. Together, our results indicate that alterations in Hippo signalling may play a role in the pathogenesis of CMT, in a manner similar to breast cancer. Hippo pathway components may therefore represent targets for the development of novel chemotherapeutic agents that could be useful for the treatment of both the human and canine diseases.</AbstractText>                <CopyrightInformation>© 2018 John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Rico</LastName>                    <ForeName>Charlène</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Département de Biomédecine Vétérinaire, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Boerboom</LastName>                    <ForeName>Derek</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Département de Biomédecine Vétérinaire, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paquet</LastName>                    <ForeName>Marilène</ForeName>                    <Initials>M</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3562-4636</Identifier>                    <AffiliationInfo>                        <Affiliation>Centre de Recherche en Reproduction et Fertilité, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Département de Pathologie et de Microbiologie, Université de Montréal, Québec, Canada.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Vet Comp Oncol</MedlineTA>            <NlmUniqueID>101185242</NlmUniqueID>            <ISSNLinking>1476-5810</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Hippo pathway</Keyword>            <Keyword MajorTopicYN="N">YAP/TAZ expression</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">canine mammary tumours</Keyword>            <Keyword MajorTopicYN="N">dogs</Keyword>            <Keyword MajorTopicYN="N">immunohistochemistry</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30117264</ArticleId>            <ArticleId IdType="doi">10.1111/vco.12432</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>